C1q (classical complement cascade initiator) is upregulated in AD brain and tags synapses for microglial phagocytosis via C3-CR3 signaling. This excessive, activity-independent pruning underlies early synaptic loss before plaque deposition. The hypothesis is supported by compelling mechanistic studies (Hong et al. 2016) and Annexon Pharmaceuticals' ANX005 antibody is in clinical development. The mechanism explains early cognitive decline independent of amyloid burden, addressing a critical thera
TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratificat
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
Complement C1q-Mediated Synaptic Pruning
9/11
dimensions won
TREM2-Deficient Microglia as Drivers of
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.79
0.80
Evidence
0.82
0.88
Novelty
0.72
0.65
Feasibility
0.78
0.85
Impact
0.80
0.82
Druggability
0.85
0.90
Safety
0.65
0.72
Competition
0.75
0.68
Data
0.78
0.85
Reproducible
0.76
0.82
KG Connect
0.30
0.53
Score Breakdown
Dimension
Complement C1q-Mediated Synapt
TREM2-Deficient Microglia as D
Mechanistic
0.790
0.800
Evidence
0.820
0.880
Novelty
0.720
0.650
Feasibility
0.780
0.850
Impact
0.800
0.820
Druggability
0.850
0.900
Safety
0.650
0.720
Competition
0.750
0.680
Data
0.780
0.850
Reproducible
0.760
0.820
KG Connect
0.304
0.533
Evidence
Complement C1q-Mediated Synaptic Pruning Drives Early Cognit
No evidence citations yet
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxic
No evidence citations yet
Debate Excerpts
Complement C1q-Mediated Synaptic Pruning Drives Ea
4 rounds · quality: 0.50
Persona-Theorist
## Theoretical Analysis: C1q-Driven Synaptic Pruning in Alzheimer's Disease
### Key Molecular Mechanisms
C1q initiates the classical complement cascade, binding directly to synapses in an activity...
Persona-Skeptic
# Critical Evaluation: C1q-Mediated Synaptic Pruning Hypothesis
## Overview
The hypothesis presents an elegant mechanistic framework linking amyloid oligomers to complement-driven synaptic loss, w...
Persona-Domain Expert
## Practical Translation Assessment: C1q as a Therapeutic Target in AD
### Druggability — Favorable but Complex
C1q is a well-characterized target with validated biology. ANX005 (Anixa Biosciences...
Persona-Synthesizer
{"hypothesis_title": "Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Decline in Alzheimer's Disease","synthesis_summary": "The C1q-mediated synaptic pruning hypothesis presents a me...
TREM2-Deficient Microglia as Drivers of Amyloid Pl
4 rounds · quality: 0.49
Persona-Theorist
# Theoretical Analysis: TREM2-Deficient Microglia in Alzheimer's Disease
## Key Molecular Mechanisms
**TREM2-DAP12 Signaling Axis**: TREM2 is a surface receptor on microglia containing an immunogl...
Persona-Skeptic
## Critical Evaluation: TREM2 Hypothesis and Theoretical Analysis
### Core Strength Acknowledged
The genetic evidence is legitimately strong by AD standards—R47H represents one of the few variants...
Persona-Domain Expert
## Practical & Translational Assessment: TREM2 Agonism in AD
### Druggability: Favorable but CNS Delivery Is Key Challenge
TREM2 is a cell-surface receptor with a well-defined extracellular immuno...
Persona-Synthesizer
{"hypothesis_title":"TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease","synthesis_summary":"The TREM2 R47H variant represents one of the most robustly replicate...